4 Healthcare Stock Stories for the Well-Being of Investors
Eli Lilly and Company (NYSE:LLY): Current price $52.88
Lilly and its wholly owned subsidiary Avid Radiopharmaceuticals, said late Tuesday that Amyvid (Florbetapir F 18 Injection) has received European Commission marketing authorization as a diagnostic radiopharmaceutical that is indicated for Positron Emission Tomography imaging of beta-amyloid neuritic plaque density in the brains of adult patients suffering from cognitive impairment who are being studied for Alzheimer’s disease and other causes of cognitive impairment. In is noted that Amyvid should be used in conjunction with a clinical evaluation.
Onyx Pharmaceuticals (NASDAQ:ONXX): Current price $79.19
On Tuesday, Onyx announced an underwritten public offering of 4.4 million shares of its common stock, and it has also granted the underwriters a 30-day option to buy up to an additional 660,000 shares in the public offering to cover any overallotments. The offering should close on or about January 22nd, subject to the usual closing conditions. Onyx intends to use the net proceeds to fund its research and development activities, clinical development programs, and sales and marketing activities to commercialize Kyprolis globally, and for general corporate purposes, including working capital.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Bristol-Myers Squibb Company (NYSE:BMY): Current price $34.34
On Wednesday, the company will initiate talks through which to resolve hundreds of millions of dollars in allegations in regards to liver-disease patients killed or harmed during a company-sponsored drug trial in 2012, according to court papers and a knowledgeable source. Bristol-Myers has received requests for medical costs and damages for 14 people injured in the evaluation which in total are in excess of $500 million, says the source.
St. Jude Medical (NYSE:STJ): Current price $34.31
The medical device firm, said on Wednesday that the FDA has approved the next-generation Merlin.net Patient Care Network, which is a secure, Internet-based remote care system for patients with implanted medical devices. The newest version of the Network gives clinicians extra insight into changes in their patients’ heart failure status via advanced impedance and lead monitoring capabilities, improving the management of patients at risk of sudden cardiac death or ventricular and atrial arrhythmias.